. "Benzylpenicillin"@en . . . . "PG"@en . . . "560ml/min in healthy humans"@en . . . . "Benzylpenicillinum"@en . . . . . "approved"@en . . . . . . . "Bind to serum proteins (45-68%), mainly albumin."@en . " "@en . "Benzylpenicillin"@en . . . . . . . . . . . . . . . . "61-33-6"@en . . "Benzylpenicillinic acid"@en . . . . . . "# Eagle H, Newman E, Musselman AD, Robinson M, Birmingham M: THE RENAL CLEARANCE OF PENICILLINS F, G, K, AND X IN RABBITS AND MAN. J Clin Invest. 1947 Sep;26(5):903-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16695494"@en . . "Benzylpenicilline"@en . . "Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms. Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as Streptococcus pneumoniae, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (S. agalactiae), S. viridans, and Enterococcus faecalis. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as Bacillus anthracis, Corynebacterium diphtheriae, and Erysipelothrix rhusiopathiae. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by Neisseria meningitidis and Pasteurella. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions. "@en . . . . " "@en . "For use in the treatment of severe infections caused by penicillin G-susceptible microorganisms when rapid and high penicillin levels are required such as in the treatment of septicemia, meningitis, pericarditis, endocarditis and severe pneumonia."@en . . . . "0.53\u20130.67 L/kg in adults with normal renal function"@en . . "Oral LD₅₀ in rat is 8900 mk/kg. Neurological adverse reactions, including convulsions, may occur with the attainment of high CSF levels of beta-lactams. Neutropenia can occur if high doses are administered consistently for over 2 weeks. "@en . "Gunter Schumacher, Peter Buckel, \"Plasmids for the increased production of penicillin G amidase.\" U.S. Patent US5053335, issued May, 1984."@en . . . "PCG"@en . . "Penicillin G"@en . . . . . . "Free penicillin ii"@en . "Enteric bacteria and other eubacteria"@en . "Streptococcus pyogenes"@en . "Rapidly absorbed following both intramuscular and subcutaneous injection. Initial blood levels following parenteral administration are high but transient. Oral absorption in fasting, healthy humans is only about 15-30% as it is very susceptible to acid-catalyzed hydrolysis."@en . "Penicillin G is eliminated by the kidneys. Nonrenal clearance includes hepatic metabolism and, to a lesser extent, biliary excretion."@en . "Staphylococcus aureus"@en . "(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"@en . "Bencilpenicilina"@en . . . . . "Staphylococcus epidermidis"@en . "In adults with normal renal function is reportedly 0.4\u20130.9 hours"@en . . "By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, penicillin G inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that penicillin G interferes with an autolysin inhibitor."@en . . . . . . . . . . "6-(2-phenylacetamido)penicillanic acid"@en .